Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 16, 2015 - Issue 18
Submit an article Journal homepage
699
Views
11
CrossRef citations to date
0
Altmetric
Drug Evaluations

Carbidopa levodopa enteral suspension

Lauren C SeebergerDepartment of Neurology, University of Colorado, Denver, CO80045, USACorrespondence[email protected]
&
Robert A HauserDepartment of Neurology, Molecular Pharmacology and Physiology, University of South Florida, Tampa, FL33613, USA
Pages 2807-2817 | Published online: 23 Nov 2015

Bibliography

  • Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers.
  • Hirtz D, Thurman DJ, Gwinn-Hardy K, et al. How common are the “common” neurologic disorders? Neurology. 2007;68(5):326–337.
  • Van Den Eeden SK, Tanner CM, Bernstein AL, et al. Incidence of Parkinson’s disease: variation by age, gender, and race/ethnicity. Am J Epidemiol. 2003;157(11):1015–1022.
  • Hauser RA. Levodopa: past, present, and future. Eur Neurol. 2009;62(1):1–8.
  • Fahn S. Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs Later L-DOPA. Arch Neurol. 1999 May;56(5):529–535.
  • Chapuis S, Ouchchane L, Metz O, et al. Impact of the motor complications of Parkinson’s disease on the quality of life. Mov Disord. 2005;20(2):224–230.
  • Storch A, Schneider CB, Wolz M, et al. Nonmotor fluctuations in Parkinson disease: severity and correlation with motor complications. Neurology 2013;80(9):800–809.
  • Nutt JG, Obeso JA, Stocchi F. Continuous dopamine-receptor stimulation in advanced Parkinson’s disease. Trends Neurosci. 2000;23(10 Suppl):S109–S115.
  • Nyholm D. The rationale for continuous dopaminergic stimulation in advanced Parkinson’s disease. Parkinsonism Relat Disord. 2007;13(Suppl):S13–S17.
  • Lieberman A, Goodgold A, Jonas S, et al. Comparison of dopa decarboxylase inhibitor (carbidopa) combined with levodopa and levodopa alone in Parkinson’s disease. Neurology. 1975;25(10):911–916.
  • Block G, Liss C, Reines S, et al. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson’s disease. A multicenter 5-year study. The CR First Study Group. Eur Neurol. 1997;37(1):23–27.
  • Stocchi F, Rascol O, Kieburtz K, et al. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol. 2010;68(1):18–27.
  • Parkinson Study Group CCI. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease. Arch Neurol. 2009;66(5):563–570.
  • Hauser RA, Rascol O, Korczyn AD, et al. Ten-year follow-up of Parkinson’s disease patients randomized to initial therapy with ropinirole or levodopa. Mov Disord. 2007;22(16):2409–2417.
  • Gershanik O, Jenner P. Moving from continuous dopaminergic stimulation to continuous drug delivery in the treatment of Parkinson’s disease. Eur J Neurol. 2012;19(12):1502–1508.
  • Pahwa R, Factor SA, Lyons KE, et al. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006;66(7):983–995.
  • Hauser RA, Hsu A, Kell S, et al. Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson’s disease and motor fluctuations: a phase 3 randomised, double-blind trial. Lancet Neurol. 2013;12(4):346–356.
  • LeWitt PA, Friedman H, Giladi N, et al. Accordion pill carbidopa/levodopa for improved treatment of advanced Parkinson’s disease symptoms [abstract]. Mov Disord. 2012;27(S1):408.
  • LeWitt PA, Giladi N, Gurevish T, et al. Accordion pill carbidopa/levodopa (AP-CD/LD) for treatment of advanced PD [abstract]. Mov Disord. 2014;29(S1):S572–S641.
  • LeWitt PA, Saint-Hilaire MH, Grosset DG, et al. Inhaled levodopa (CVT‐301) provides rapid motor improvements after administration to Parkinson’s disease patients when OFF [abstract]. Mov Disord. 2015;30(S1):S568–S633.
  • Hauser RA, Dubow J, Dzyngel B, et al. Efficacy of sublingual apomorphine (APL‐130277) for the treatment of “off” episodes in patients with Parkinson’s disease [abstract]. Mov Disord. 2015;30(S1):S568–S633.
  • Giladi N, Caraco Y, Gurevich T, et al. Pharmokinetic profile of ND0612 (levodopa/carbidopa for subcutaneous infusion) in patients with moderate to severe Parkinson’s disease [abstract]. Mov Disord. 2015;30(S1):S568–S633.
  • Clarke CE, Worth P, Grosset D, et al. Systematic review of apomorphine infusion, levodopa infusion and deep brain stimulation in advanced Parkinson’s disease. Parkinsonism Relat Disord. 2009;15(10):728–741.
  • Martinez-Martin P, Reddy P, Katzenschlager R, et al. EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson’s disease. Mov Disord. 2015;30(4):510–516.
  • Odin P, Ray Chaudhuri K, Slevin JT, et al. Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson’s disease: consensus from an international survey and discussion program. Parkinsonism Relat Disord. 2015;21(10):1133–1144.

• international consensus paper on non-oral PD therapy

  • Antonini A, Odin P. Pros and cons of apomorphine and L-dopa continuous infusion in advanced Parkinson’s disease. Parkinsonism Relat Disord. 2009;15(Suppl 4):S97–S100.
  • Nyholm D, Odin P, Johansson A, et al. Pharmacokinetics of levodopa, carbidopa, and 3-O-methyldopa following 16-hour jejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson’s disease patients. AAPS J. 2013;15(2):316–323.
  • Kurth MC, Tetrud JW, Tanner CM, et al. Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson’s disease patients with ‘on-off’ fluctuations. Neurology. 1993;43(9):1698–1703.
  • Nyholm D, Askmark H, Gomes-Trolin C, et al. Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets. Clin Neuropharmacol. 2003;26(3):156–163.
  • Lennernas H, Nilsson D, Aquilonius SM, et al. The effect of L-leucine on the absorption of levodopa, studied by regional jejunal perfusion in man. Br J Clin Pharmacol. 1993;35(3):243–250.
  • Nyholm D, Lennernas H, Gomes-Trolin C, et al. Levodopa pharmacokinetics and motor performance during activities of daily living in patients with Parkinson’s disease on individual drug combinations. Clin Neuropharmacol. 2002;25(2):89–96.
  • Contin M, Riva R, Albani F, et al. Pharmacokinetic optimisation in the treatment of Parkinson’s disease. Clin Pharmacokinet. 1996;30(6):463–481.
  • Seeberger LC, Hauser RA. Optimizing bioavailability in the treatment of Parkinson’s disease. Neuropharmacology. 2007;53(7):791–800.
  • Contin M, Martinelli P. Pharmacokinetics of levodopa. J Neurol. 2010;257(Suppl 2):S253–S261.
  • Sage JI, Schuh L, Heikkila RE, et al. Continuous duodenal infusions of levodopa: plasma concentrations and motor fluctuations in Parkinson’s disease. Clin Neuropharmacol. 1988;11(1):36–44.
  • Samanta J, Hauser RA. Duodenal levodopa infusion for the treatment of Parkinson’s disease. Expert Opin Pharmacother. 2007;8(5):657–664.
  • Palhagen SE, Dizdar N, Hauge T, et al. Interim analysis of long-term intraduodenal levodopa infusion in advanced Parkinson disease. Acta Neurol Scand. 2012;126(6):e29–e33.
  • Santos-Garcia D, Anon MJ, Fuster-Sanjurjo L, et al. Duodenal levodopa/carbidopa infusion therapy in patients with advanced Parkinson’s disease leads to improvement in caregivers’ stress and burden. Eur J Neurol. 2012;19(9):1261–1265.
  • Fernandez HH, Vanagunas A, Odin P, et al. Levodopa-carbidopa intestinal gel in advanced Parkinson’s disease open-label study: interim results. Parkinsonism Relat Disord. 2013;19(3):339–345.
  • Foltynie T, Magee C, James C, et al. Impact of duodopa on quality of life in advanced Parkinson’s disease: a UK case series. Parkinson’s Dis. 2013;2013:362908.
  • Sensi M, Preda F, Trevisani L, et al. Emerging issues on selection criteria of levodopa carbidopa infusion therapy: considerations on outcome of 28 consecutive patients. J Neural Transm. 2014;121(6):633–642.
  • Antonini A, Yegin A, Preda C, et al. Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson’s disease patients; 12-month interim outcomes. Parkinsonism Relat Disord. 2015;21(3):231–235.
  • Olanow CW, Kieburtz K, Odin P, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. 2014;13(2):141–149.

•• only double blind trial of therapy of LCIG

  • Fernandez HH, Standaert DG, Hauser RA, et al. Levodopa-carbidopa intestinal gel in advanced Parkinson’s disease: final 12-month, open-label results. Mov Disord. 2015;30(4):500–509.

•• pivotal trial for US approval of CLES

  • Slevin JT, Fernandez HH, Zadikoff C, et al. Long-term safety and maintenance of efficacy of levodopa-carbidopa intestinal gel: an open-label extension of the double-blind pivotal study in advanced Parkinson’s disease patients. J Parkinson’s Dis. 2015;5(1):165–174.
  • Stowe R, Ives N, Clarke CE, et al. Meta-analysis of the comparative efficacy and safety of adjuvant treatment to levodopa in later Parkinson’s disease. Mov Disord. 2011;26(4):587–598.
  • Antonini A, Fung VSC, Boyd JT, et al. Changes in “on” time with levodopa-carbidopa intestinal gel infusion in advanced Parkinson’s disease patients with troublesome dyskinesia. Ann Neurol. 2013;74:S45–S45.
  • Nyholm D, Klangemo K, Johansson A. Levodopa/carbidopa intestinal gel infusion long-term therapy in advanced Parkinson’s disease. Eur J Neurol. 2012;19(8):1079–1085.

• longest retrospective study of LCIG

  • Zibetti M, Merola A, Artusi CA, et al. Levodopa/carbidopa intestinal gel infusion in advanced Parkinson’s disease: a 7-year experience. Eur J Neurol. 2014;21(2):312–318.
  • Martinez-Martin P. The importance of non-motor disturbances to quality of life in Parkinson’s disease. J Neurol Sci. 2011;310(1–2):12–16.
  • Zibetti M, Rizzone M, Merola A, et al. Sleep improvement with levodopa/carbidopa intestinal gel infusion in Parkinson disease. Acta Neurol Scand. 2013;127(5):e28–e32.
  • Busk K, Nyholm D. Long-term 24-h levodopa/carbidopa gel infusion in Parkinson’s disease. Parkinsonism Relat Disord. 2012;18(8):1000–1001.
  • Negreanu LM, Popescu BO, Babiuc RD, et al. Cutting the Gordian knot: the blockage of the jejunal tube, a rare complication of Duodopa infusion treatment. J Med Life. 2010;3(2):191–192.
  • Krones E, Zollner G, Petritsch W. Knotting of percutaneous endoscopic jejunostomy feeding tubes in two patients with Parkinson’s disease and continuous Duodopa(R) treatment. Z Gastroenterol. 2012;50(2):213–216.
  • Del-Hoyo-Francisco J, Bustamante-Balen M, Martinez-Torres I, et al. Knotting of Duodopa(R) duodenal infusion system. Rev Esp Enferm Dig. 2015;107(5):323–324.
  • Bianco G, Vuolo G, Ulivelli M, et al. A clinically silent, but severe, duodenal complication of duodopa infusion. J Neurol Neurosurg Psychiatry. 2012;83(6):668–670.
  • Stathis P, Tzias V, Argyris P, et al. Gastric bezoar complication of Duodopa((R)) therapy in Parkinson’s disease, treated with Coca-Cola((R)). Mov Disord. 2014;29(8):1087–1088.
  • Urban PP, Wellach I, Faiss S, et al. Subacute axonal neuropathy in Parkinson’s disease with cobalamin and vitamin B6 deficiency under duodopa therapy. Mov Disord. 2010;25(11):1748–1752.
  • Nyholm D. Duodopa(R) treatment for advanced Parkinson’s disease: a review of efficacy and safety. Parkinsonism Relat Disord. 2012;18(8):916–929.
  • Galazky I, Schoof J, Stallforth S, et al. Guillain-Barre/CIDP-like neuropathy in two parkinsonian patients following intestinal levodopa/carbidopa treatment. Parkinsonism Relat Disord. 2014;20(1):125–127.
  • Lehnerer SM, Fietzek UM, Messner M, et al. Subacute peripheral neuropathy under duodopa therapy without cobalamin deficiency and despite supplementation. J Neural Transm. 2014;121(10):1269–1272.
  • Uncini A, Eleopra R, Onofrj M. Polyneuropathy associated with duodenal infusion of levodopa in Parkinson’s disease: features, pathogenesis and management. J Neurol Neurosurg Psychiatry. 2015;86(5):490–495.
  • Merola A, Zibetti M, Rizzone MG, et al. Prospective assessment of peripheral neuropathy in Duodopa-treated parkinsonian patients. Acta Neurol Scand. 2014;129(1):e1–e5.
  • Mancini F, Comi C, Oggioni GD, et al. Prevalence and features of peripheral neuropathy in Parkinson’s disease patients under different therapeutic regimens. Parkinsonism Relat Disord. 2014;20(1):27–31.
  • Muller T, van Laar T, Cornblath DR, et al. Peripheral neuropathy in Parkinson’s disease: levodopa exposure and implications for duodenal delivery. Parkinsonism Relat Disord. 2013;19(5):501–507, discussion 01.
  • Nyholm D, Lewander T, Johansson A, et al. Enteral levodopa/carbidopa infusion in advanced Parkinson disease: long-term exposure. Clin Neuropharmacol. 2008;31(2):63–73.
  • Devos D, French DSG. Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson’s disease. Mov Disord. 2009;24(7):993–1000.
  • Calandrella D, Romito LM, Elia AE, et al. Causes of withdrawal of duodenal levodopa infusion in advanced Parkinson disease. Neurology 2015;84(16):1669–1672.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.